Eevia Health

The study of the bioactivity of the Eevia top extracts was done on Eurofin’s BioMAP® Human Primary Cell Phenotypic profiling platform. The Eurofins platform contains over 150 biomarkers across a range of bioactivity systems. For each of Eevia’s main product lines, a competitor product was also tested. The competitor compounds were tested in the exact same way as Eevia’s extracts in this study and then these were compared in pairs.

"This study is valuable and compelling in that it gives us a scientific basis for understanding the bioactivity of our extracts, while it also confirms that we measure up well with competitors. From a regulatory perspective, it may be a novel approach to demonstrating herbal equivalency. For Eevia, it is simply a straightforward way to demonstrate what bioactivity our extracts may have in the human body and to benchmark against competition. It is also a rational step to guide further substantiation efforts from the most striking data in the study.” comments Stein Ulve, CEO of Eevia Health Plc.

The BioMAP Platform

The BioMAP® Platform has been validated with clinically approved drugs and over 4,500 references. It provides biopharma and nutraceutical decision-makers with preclinical human data for insights on efficacy, safety, and clinical superiority. The phenotypic approach can help elucidate the mechanism of action and safety pharmacology to adaptive immunity, immuno-modulation, and more.

The BioMAP® panels consist of human primary cell-based systems designed to model different aspects of the human body in an in vitro format. There are twelve (12) systems in the Diversity PLUS panel which allow for test agent characterization in an unbiased way across a broad set of systems modeling various human disease states.

A description of the way the Platform has been constructed is shown in the picture below:

​​​

 

The BioMAP® study Eevia did with Eurofins included 12 different extracts and provided a large amount of scientific data. It will take time to interpret and analyze all the data. However, significant positive conclusions can already be drawn.

As an example, Eevia’s pine bark extract Fenoprolic® 70 Organic was compared with the best-selling pine bark extract in the industry. It is a product which has sales of over EUR 300 million. The competitor extract is referred to as EEV_(11) PYC in the study.

In the picture below, an overlay of Eevia’s Fenoprolic 70 Organic (referred to as EV_(4) FP70) at 11000 ng/ml and the selected reference benchmark EEV_(11) PYC at 11000 ng/ml is shown:

As one can see, the two extracts have very similar bioactivity. There were 40 common activities between the two pine bark extracts within nine systems. Three differentiating activities were annotated within the following systems: LPS (IL-1α) a Chronic Inflammation system, SAg (CD69) an inflammation system for autoimmune conditions, and BF4T (Eotaxin 3) a system relevant for lung conditions and allergies. Two of the three systems showed stronger bioactivity with the Eevia pine bark extract.

For further information, please contact:

Stein Ulve, CEO, Eevia Health Plc                          

Email: stein.ulve@eeviahealth.com                      

Telephone: +358 400 22 5967                         

INFORMATION ABOUT EEVIA HEALTH PLC

Eevia Health Plc, founded in March 2017, addresses significant health problems with bioactive compounds extracted from plant materials. The materials are primarily wild harvested from the pristine Finnish and Swedish forests near or above the Arctic Circle. The extracts are sold B2B as ingredients in dietary supplements and food brands globally. These global brands utilize the ingredients in their consumer product formulas.

Eevia Health is a manufacturer of 100% organically certified plant extracts. Although a significant product, Elderberry extract, is made from cultivated berries, most of Eevia’s other raw materials, such as bilberry, lingonberry, chaga-mushroom, and pine bark, are wild-harvested in a sustainable fashion.

Eevia Health operates a modern green-chemistry production facility in Finland. Manufacturing natural ingredients near the raw material harvest areas, Eevia offers a short value chain with an environmentally friendly carbon footprint, competitive pricing, and extreme transparency. Eevia listed its shares at Spotlight Stock Market in Sweden in June 2021, with the short name (ticker) EEVIA.

To learn more, please visit  www.eeviahealth.com or follow Eevia Health on LinkedIn@EeviaHealth.